title: [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
abstract: OBJECTIVE
  We searched for a correlation between serum S100B protein and cutaneous malignant melanoma stage, according to the American Joint Committee on Cancer staging system, and between elevation of serum S100B protein and development of metastasis.
  
  
  METHODS
  We conducted a prospective bicentric study for 20 months in 122 patients with malignant melanoma. LIA-mat(R) assay was used to determine serum S100B at each examination. The optimal cut-off value was determined from the ROC curve.
  
  
  RESULTS
  The optimal cut-off value to discriminate patients with metastases from patients in remission was 0.09 microg/l. Sensitivity was 46 p. 100 in patients with stage III and 86 p. 100 in patients with stage IV disease. The positive predictive value for stage III/IV was 77 p. 100 and the negative predictive value was 89 p. 100. Serial measurements were made in 56 patients. The serum S100B protein level was elevated in 69 p. 100 of the patients disclosing disease progression (9/13). In 44 p. 100 of the patients (4/9), serum S100B protein level rose within a delay of 3 months before new metastases were detected.
  
  
  CONCLUSIONS
  Our study confirms that serum S100B protein is a tumor marker for melanoma staging and follow-up. A rise in S100B protein precedes or reveals metastasis.
authors.affiliation: Service de Dermatologie, Hôpital de Pontchaillou, CHU, 35033 Rennes.
authors.forename: M
authors.initials: M
authors.lastname: Brouard
authors.forename: V
authors.initials: V
authors.lastname: Quillien
authors.forename: I
authors.initials: I
authors.lastname: Ollivier
authors.forename: T
authors.initials: T
authors.lastname: Lesimple
authors.forename: H
authors.initials: H
authors.lastname: Adamski
authors.forename: J
authors.initials: J
authors.lastname: Chevrant-Breton
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D002135:Calcium-Binding Proteins / Q000097:blood*; D005500:Follow-Up Studies; D006801:Humans; D008545:Melanoma / Q000097:blood* / Q000473:pathology*; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000175:diagnosis; D009414:Nerve Growth Factors / Q000097:blood*; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D012372:ROC Curve; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; D012878:Skin Neoplasms / Q000097:blood* / Q000473:pathology; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor; D002135:Calcium-Binding Proteins; D009414:Nerve Growth Factors; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; C579160:S100B protein, human